SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
AMENDMENT NO. 2*
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES
13d-1 (b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)
HEMISPHERX BIOPHARMA, INC.
--------------------------
(Name of Issuer)
COMMON STOCK, $.001 PAR VALUE
------------------------------
(Title of Class of Securities)
42366C103
--------------
(CUSIP Number)
June 8, 2000
------------------------------------------------------
(Date of Event Which Requires Filing of this Statement
Check the appropriate box to designate the rule
pursuant to which this schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE>
CUSIP No. 42366C103
---------------------------------------------------------------------------
1. Names of Reporting Persons, S. S. or I. R. S. Identification Nos. of Above
Persons
Jerome Belson
---------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) N/A
(b) N/A
---------------------------------------------------------------------------
3. SEC Use Only
---------------------------------------------------------------------------
4. Citizenship or Place of Organization: United States of America
---------------------------------------------------------------------------
Number of Shares Owned by Each Reporting Person with
5. Sole Voting Power: 760,205 shares of Common Stock consisting of 474,505
shares of common stock and 285,700 shares of common stock underlying
certain warrants. Mr. Belson has given an irrevocable proxy to William A.
Carter, President of Hemispherx Biopharma, to vote 50,000 shares of Mr.
Belson's common stock.
---------------------------------------------------------------------------
6. Shared Voting Power: N/A
---------------------------------------------------------------------------
7. Sole Dispositive Power: 760,205 shares of Common Stock
---------------------------------------------------------------------------
8. Shared Dispositive Power: N/A
---------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person: 760,205
shares of Common Stock, without par value
---------------------------------------------------------------------------
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares: N/A
---------------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row (9): 2.6 %
---------------------------------------------------------------------------
2
<PAGE>
12. Type of Reporting Person: IN
---------------------------------------------------------------------------
Item 1.
1(a). Name of Issuer. Hemispherx Biopharma, Inc.
1(b). Address of Issuer's Principal Executive Offices.
One Penn Center
1617 JFK Blvd., Suite 660
Philadelphia, PA 19103
Item 2.
2(a). Name of Person Filing. Jerome Belson
2(b). Address of Principal Business Office.
495 Broadway - 6th Floor
New York, New York 10012
2(c). Citizenship. United States of America
2(d). Title of Class of Securities. Common Stock, $.001 par value.
2(e). CUSIP Number. 42366C103
Item 3. N/A
Item 4. Ownership.
(a) Amount Beneficially Owned: 760,205
(b) Percent of Class: 2.6 %
(c) Number of Shares as to which such person has:
(i) Sole power to vote or to direct the vote 760,205
(ii) Shared power to vote or to direct the vote 0.
(iii) Sole power to dispose or to direct the disposition of 760,205
(iv) Shared power to dispose or to direct the disposition of 0.
3
<PAGE>
Item 5. Ownership of Five Percent or Less of a Class. [X]
Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company. N/A
Item 8. Identification and Classification of Members of a Group. N/A
Item 9. Notice of Dissolution of Group: N/A
Item 10. Certification:
(b) The following certification shall be included if the statement is
filed pursuant to rule 13d-1(c).
By signing below, I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and were not held for the
purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction have that purpose or effect.
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
July 5, 2000
-----------------------------
(Date)
/s/ Jerome Belson
-----------------------------
(Signature)
Jerome Belson
-----------------------------
(Name/Title)
The original statement shall be signed by each person on whose behalf the
statement is filed or his authorized representative. If the statement is signed
on behalf of a person by his authorized representative (other than an executive
officer or general partner of this filing person), evidence of the
representative's authority to sign on behalf of such person shall be filed with
the statement, provided, however, that a power of attorney for this purpose
which is already on file with the Commission may be incorporated by reference.
The name and any title of each person who signs the statement shall be typed or
printed beneath his signature.
Attention: Intentional misstatements or omissions of fact constitute Federal
criminal violations (See 18 U. S. C. 1001).
4
